Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018

Press Release

View printer-friendly version
<< Back
Apr 25,2018
Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018

CAMBRIDGE, Mass., April 25, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 2, 2018 to report its first quarter 2018 financial results and provide a corporate update.


To access the live conference call, please dial 1-855-728-4793 (domestic) or 1-503-343-6666 (international), and refer to conference ID 7572918. A webcast of the call will also be available under "Events and Presentations" in the Investors section of the Blueprint Medicines website at The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing multiple programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit

Cision View original content with multimedia:

SOURCE Blueprint Medicines Corporation

Investor and Media Relations Contacts: Kristin Hodous, 617-714-6674,, Jim Baker, 617-844-8236,